Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences
07:13am, Monday, 11'th Oct 2021
Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
07:00am, Monday, 11'th Oct 2021
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Oct 2021
BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
04:30pm, Wednesday, 08'th Sep 2021
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
09:00am, Friday, 03'rd Sep 2021
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone aceto
Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know
01:43pm, Monday, 30'th Aug 2021
Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?
01:18pm, Wednesday, 25'th Aug 2021
Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy. Related: Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patient
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
07:30am, Wednesday, 25'th Aug 2021
BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301
7 Penny Stocks with Millionaire-Maker Potential
01:36pm, Monday, 23'rd Aug 2021
These penny stocks have multiple growth drivers powering their businesses. That will push their prices to record heights in the future.
Why Flexion Therapeutics (FLXN) Could Be an Impressive Growth Stock
10:39am, Tuesday, 17'th Aug 2021
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Flexion Therapeutics (FLXN).
Down 24.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Flexion Therapeutics (FLXN)
11:26am, Monday, 16'th Aug 2021
The heavy selling pressure might have exhausted for Flexion Therapeutics (FLXN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q2 2021 Results - Earnings Call Transcript
10:46pm, Wednesday, 04'th Aug 2021
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q2 2021 Results - Earnings Call Transcript
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
04:15pm, Thursday, 29'th Jul 2021
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S.
